Table of Contents
<< Previous Issue | Oct 2016 (Vol: 2016, Issue: 10) | Next Issue >> |
- Section: Licensing
-
Hanmi Partners RAF inhibitor HM95573 with Genentech in a deal worth US$910 M
-
Teva Tries its Luck with Risky NGF Inhibitor Class by Partnering with Regeneron
-
Amgen Bolsters its CV Pipeline with Arrowhead’s RNA Interference Therapies
-
AstraZeneca Streamlines Portfolio with Four More Externalisation Deals